Vitamin D compounds in leukemia
- 8 August 2005
- journal article
- review article
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 97 (1-2) , 195-202
- https://doi.org/10.1016/j.jsbmb.2005.06.017
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- Retinoblastoma Protein and CCAAT/Enhancer-Binding Protein β Are Required for 1,25-Dihydroxyvitamin D3-Induced Monocytic Differentiation of HL60 CellsCancer Research, 2004
- Combination of 22-oxa-1,25-dihydroxyvitamin D3, a vitamin D3 derivative, with vitamin K2 (VK2) synergistically enhances cell differentiation but suppresses VK2-inducing apoptosis in HL-60 cellsLeukemia, 2002
- Leukemia Cell DifferentiationGeneral Pharmacology: The Vascular System, 1999
- Inhibition of intestinal tumor development in rat multi-organ carcinogenesis and aberrant crypt foci in rat colon carcinogenesis by 22-oxa-calcitriol, a synthetic analogue of 1α,25-dihydroxyvitamin D3Carcinogenesis: Integrative Cancer Research, 1995
- Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3Endocrinology, 1995
- The Role of the Vitamin D Endocrine System in Health and DiseaseNew England Journal of Medicine, 1989
- VITAMIN D AND BREAST CANCERThe Lancet, 1989
- 1,25-Dihydroxyvitamin D3 modulates the expression of a lymphokine (granulocyte-macrophage colony-stimulating factor) posttranscriptionally.Journal of Clinical Investigation, 1988
- Granulocyte-macrophage colony-stimulating factor. Sensitive and receptor-mediated regulation by 1,25-dihydroxyvitamin D3 in normal human peripheral blood lymphocytes.Journal of Clinical Investigation, 1987
- γ-interferon stimulates production of 1,25-dihydroxyvitamin D3 by normal human macrophagesBiochemical and Biophysical Research Communications, 1985